Description
Apararenone is a nonsteroidal mineralocorticoid receptor antagonist.
Apararenone
Product ID A601022
Cas No. 945966-46-1
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 945966-46-1 |
|---|---|
| Purity | ≥98% |
| Formula | C17H17FN2O4S |
| Formula Wt. | 364.39 |
| Chemical Name | N-(4-(4-Fluorophenyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)methanesulfonamide |
| IUPAC Name | N-[4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-1,4-benzoxazin-7-yl]methanesulfonamide |
| Synonym | MT3995; CHEMBL2181929; 832663U2NB; Methanesulfonamide, N-(4-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-7-yl)- |
| Solubility | Insoluble in water. Soluble in DMSO (>80 mg /mL). |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Iijima T, Katoh M, Takedomi K, et al. Discovery of apararenone (MT-3995) as a highly selective, potent, and novel nonsteroidal mineralocorticoid receptor antagonist. J Med Chem. 2022 Jun 23;65(12):8127-8143. PMID: 35652647.
Wada T, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol. 2021 Feb;25(2):120-130. PMID: 32974732.